Carlsson A
Department of Pharmacology, University of Göteborg, Sweden.
Neuropsychopharmacology. 1988 Sep;1(3):179-86. doi: 10.1016/0893-133x(88)90012-7.
The dopamine hypothesis of schizophrenia is still almost entirely based on pharmacologic evidence. Even though a disturbed dopamine function has not yet been established beyond doubt in schizophrenia, recent basic research on dopaminergic mechanisms opens up possibilities for the development of more sophisticated pharmacologic tools, capable of discovering subtypes of dopamine receptors, which may turn out to be abnormal in schizophrenia. Such tools may also prove therapeutically useful. Schizophrenia is probably a heterogeneous group of disorders with mixed biopathology. To facilitate the search for nondopaminergic mechanisms of possible pathogenetic importance in subgroups of schizophrenia, a hypothetical model is presented that tries to explain the role of subcortical dopaminergic pathways for mental functions and their interaction with other systems. It is proposed that corticostriatothalamocortical negative feedback loops, also involving the mesencephalic reticular formation, are modulated by mesostriatal dopamine pathways to control a thalamic filter mechanism. The psychotomimetic actions of dopaminergic agents and phencyclidine may be due to interference with these feedback mechanisms.
精神分裂症的多巴胺假说几乎仍然完全基于药理学证据。尽管多巴胺功能紊乱在精神分裂症中尚未得到确凿证实,但近期关于多巴胺能机制的基础研究为开发更精密的药理学工具开辟了可能性,这些工具能够发现多巴胺受体的亚型,而这些亚型在精神分裂症中可能是异常的。此类工具或许也将证明具有治疗价值。精神分裂症可能是一组具有混合生物病理学特征的异质性疾病。为便于探寻精神分裂症亚组中可能具有致病重要性的非多巴胺能机制,本文提出一个假说模型,试图解释皮质-纹状体-丘脑-皮质负反馈回路(该回路也涉及中脑网状结构)如何受中脑纹状体多巴胺通路调节,从而控制丘脑过滤机制。多巴胺能药物和苯环己哌啶的拟精神病作用可能是由于对这些反馈机制的干扰。